HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

Abstract
Imatinib mesylate (Gleevec), an inhibitor of the BCR-ABL tyrosine kinase, was introduced recently into the therapy of chronic myeloid leukemia (CML). Several cases of emergence of clonal chromosomal abnormalities after therapy with imatinib have been reported, but their incidence, etiology and prognosis remain to be clarified. We report here a large series of 34 CML patients treated with imatinib who developed Philadelphia (Ph)-negative clones. Among 1001 patients with Ph-positive CML treated with imatinib, 34 (3.4%) developed clonal chromosomal abnormalities in Ph-negative cells. Three patients were treated with imatinib up-front. The most common cytogenetic abnormalities were trisomy 8 and monosomy 7 in twelve and seven patients, respectively. In 15 patients, fluorescent in situ hybridization with specific probes was performed in materials archived before the initiation of imatinib. The Ph-negative clone was related to previous therapy in three patients, and represented a minor pre-existing clone that expanded after the eradication of Ph-positive cells with imatinib in two others. However, in 11 patients, the new clonal chromosomal abnormalities were not detected and imatinib may have had a direct effect. No myelodysplasia was found in our cohort. With a median follow-up of 24 months, one patient showed CML acceleration and two relapsed.
AuthorsC Terre, V Eclache, P Rousselot, M Imbert, C Charrin, C Gervais, M J Mozziconacci, O Maarek, H Mossafa, N Auger, N Dastugue, P Talmant, J Van den Akker, C Leonard, F N'Guyen Khac, F Mugneret, F Viguié, M Lafage-Pochitaloff, J N Bastie, G L Roux, F Nicolini, F Maloisel, N Vey, G Laurent, C Recher, M Vigier, Y Yacouben, S Giraudier, J P Vernant, B Salles, J Roussi, S Castaigne, V Leymarie, G Flandrin, M Lessard, France Intergroupe pour la Leucemie Myeloide Chronique
JournalLeukemia (Leukemia) Vol. 18 Issue 8 Pg. 1340-6 (Aug 2004) ISSN: 0887-6924 [Print] England
PMID15190256 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
Topics
  • Adult
  • Aged
  • Aneuploidy
  • Benzamides
  • Chromosome Aberrations
  • Chromosomes, Human, Pair 7
  • Chromosomes, Human, Pair 8
  • Clone Cells (pathology)
  • Female
  • Humans
  • Imatinib Mesylate
  • Incidence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics)
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (genetics, pathology)
  • Male
  • Middle Aged
  • Piperazines (therapeutic use)
  • Prognosis
  • Pyrimidines (therapeutic use)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: